GlassScriptPhysician profile
Derick Sonjong
NPI 1851047690
$3,656.21
in general payments reported to CMS, 2019-2025
15 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $660 · 2023: $924 · 2024: $744 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.28 |
| Education | $131.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.99 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $507.16 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $485.29 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $473.29 | 2022-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $369.25 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $313.43 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $311.21 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $106.64 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $98.82 | 2024-2025 | Invega Sustenna |
| Corium, LLC | $98.33 | 2023-2025 | Azstarys |
| Indivior INC. | $97.54 | 2024-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $60.95 | 2025 | Cobenfy |
| Almatica Pharma LLC | $43.45 | 2024-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $23.10 | 2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.76 | 2024 | Abilify Asimtufii, Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derick Sonjong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.